ESMO Events 2024

Meetings Wird in neuem Tab/Fenster geöffnet | ESMO Wird in neuem Tab/Fenster geöffnet

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

ESMO European Multidisciplinary Congress on Urological Cancers 2024 Wird in neuem Tab/Fenster geöffnet

Top experts in medical oncology, pathology, radiation oncology, radiology, nuclear medicine, and urology gather at the congress to offer their special insights on best practices, developments in major trials, and breakthroughs.

EMUC24 will identify cutting-edge therapies, examine current practices, address controversies, and review emerging technologies.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial Wird in neuem Tab/Fenster geöffnet N.M. Tannir ∙ L. Albigès ∙ D.F. McDermott ∙ M. Burotto4 ∙ T.K. Choueiri ∙ H.J. Hammers ∙ P. Barthélémy ∙ E.R. Plimack ∙ C. Porta10, ∙ S. George ∙ F. Donskov ∙ M.B. Atkins ∙ H. Gurney ∙ C.K. Kollmannsberger ∙ M.-O. Grimm ∙ C. Barrios ∙ Y. Tomita ∙ D. Castellano ∙ V. Grünwald ∙ B.I. Rini ∙ R. Jiang ∙ H. Desilva ∙ V. Fedorov ∙ C.-W. Lee ∙ R.J. Motze

• Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial Wird in neuem Tab/Fenster geöffnet C.S. Groeneveld ∙ C. Pfister ∙ S. Culine ∙ V. Harter ∙ C. Krucker ∙ J. Fontugne ∙ V. Dixon ∙ N. Sirab ∙ I. Bernard-Pierrot ∙ A. de Reyniès ∙ F. Radvanyi ∙ Y. Allory for the VESPER trial investigators

ESMO Open

• Androgen receptor pathway inhibitors and drug–drug interactions in prostate cancer Wird in neuem Tab/Fenster geöffnet H. Bolek ∙ S.C. Yazgan ∙ E. Yekedüz ∙ M.D. Kaymakcalan ∙ R.R. McKay ∙ S. Gillessen ∙ Y. Ürün

• Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a random phase II study Wird in neuem Tab/Fenster geöffnet A. Rodriguez-Vida ∙ B.P. Valderrama ∙ D. Castellano ∙ A. Pinto ∙ B. Mellado ∙ J. Puente ∙ M.A. Climent ∙ M. Domenech ∙ F. Vazquez ∙ J.L. Perez-Gracia ∙ T. Bonfill ∙ R. Morales-Barrera ∙ E. Gonzalez-Billalabeitia ∙ X. Garcia-del-Muro ∙ P. Maroto ∙ N. Navarro-Gorro ∙ N. Juanpere ∙ O. Juan ∙ J. Bellmunt Joaquim

ESMO Real World Data and Digital Oncology

• EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain Wird in neuem Tab/Fenster geöffnet R. Fernández Rodríguez ∙ N. Sagastibeltza ∙ E. Pujol Obis ∙ N. Lainez Milagro ∙ R. Sánchez-Escribano ∙ M. Martínez Kareaga ∙ J.A. Verdún Aguilar ∙ M. Arruti Ibarbia ∙ M. Pumares González ∙ T. de Portugal Fernández del Rivero ∙ A. Lacalle Emborujo∙ I. Gil Arnaiz ∙ A. Pereira-Elorrieta ∙ C. Álvarez Fernández ∙ I. Duran ∙ GONORTE Collaborative Group

• Using real world data to bridge the evidence gap left by prostate cancer screening trials Wird in neuem Tab/Fenster geöffnet N. Norori ∙ N. Burns-Cox,† ∙ L. Blaney,† ∙ N. Mayor,‡ ∙ A. Rylance ∙ T.T. Shah, ∙ A. Naranjo ∙ M.D. Hobbs

ESMO affiliated journals

• Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives Wird in neuem Tab/Fenster geöffnet Erman Akkusa, ∙ Çağatay Arslanc ∙ Yüksel Ürüna

• Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma Wird in neuem Tab/Fenster geöffnet Patricia Rioja ∙ M. Rey-Cardenasb ∙ Guillermo De Velascoc

• Integrated analysis of older adults and patients with renal dysfunction in the IMpower130 and IMpower132 randomized controlled trials for advanced non-squamous non-small cell lung cancer Wird in neuem Tab/Fenster geöffnet Makoto Nishioa ∙ Satoshi Watanabeb ∙ Hibiki Udagawac ∙ Naoko Araganed ∙ Yuki Nakagawae ∙ Yuki Kobayashie ∙ Haruhiro Saitof

• SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program Wird in neuem Tab/Fenster geöffnet Timothy J. Voorhees ∙ Evandro Bezerra ∙ Nathan Denlinger ∙ Samantha Jaglowski ∙ Marcos de Lima

• Expert opinion on managing adverse reactions associated with acalabrutinib therapy: A Delphi consensus from France Wird in neuem Tab/Fenster geöffnet Loïc Ysebaert ∙ Stéphane Ederhy ∙ Véronique Leblond ∙ Stéphanie Malartre ∙ Anaïs Portalier ∙ Vincent Sibaud ∙ Cécile Tomowiak ∙ Jérémie Zerbit on behalf of the Delphi Acalabrutinib Safety Study Group

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.